277 related articles for article (PubMed ID: 25851099)
21. Safinamide for the treatment of Parkinson's disease.
Dézsi L; Vécsei L
Expert Opin Investig Drugs; 2014 May; 23(5):729-42. PubMed ID: 24650154
[TBL] [Abstract][Full Text] [Related]
22. An expert opinion on safinamide in Parkinson's disease.
Onofrj M; Bonanni L; Thomas A
Expert Opin Investig Drugs; 2008 Jul; 17(7):1115-25. PubMed ID: 18549347
[TBL] [Abstract][Full Text] [Related]
23. Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia.
Gardoni F; Morari M; Kulisevsky J; Brugnoli A; Novello S; Pisanò CA; Caccia C; Mellone M; Melloni E; Padoani G; Sosti V; Vailati S; Keywood C
J Pharmacol Exp Ther; 2018 Dec; 367(3):442-451. PubMed ID: 30291173
[TBL] [Abstract][Full Text] [Related]
24. Safinamide: a new hope for Parkinson's disease?
Teixeira FG; Gago MF; Marques P; Moreira PS; Magalhães R; Sousa N; Salgado AJ
Drug Discov Today; 2018 Mar; 23(3):736-744. PubMed ID: 29339106
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety evaluation of safinamide as an add-on treatment to levodopa for parkinson's disease.
Kurihara K; Mishima T; Fujioka S; Tsuboi Y
Expert Opin Drug Saf; 2022 Feb; 21(2):137-147. PubMed ID: 34597253
[TBL] [Abstract][Full Text] [Related]
26. The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease.
Perez-Lloret S; Rascol O
Expert Rev Neurother; 2016; 16(3):245-58. PubMed ID: 26849427
[TBL] [Abstract][Full Text] [Related]
27. Safinamide for symptoms of Parkinson's disease.
Müller T
Drugs Today (Barc); 2015 Nov; 51(11):653-9. PubMed ID: 26744740
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study.
Hattori N; Tsuboi Y; Yamamoto A; Sasagawa Y; Nomoto M;
Parkinsonism Relat Disord; 2020 Jun; 75():17-23. PubMed ID: 32446176
[TBL] [Abstract][Full Text] [Related]
29. Safinamide as an adjunct therapy in older patients with Parkinson's disease: a retrospective study.
Lo Monaco MR; Petracca M; Vetrano DL; Di Stasio E; Fusco D; Ricciardi D; Laudisio A; Zuccalà G; Onder G; Bentivoglio AR
Aging Clin Exp Res; 2020 Jul; 32(7):1369-1373. PubMed ID: 31981101
[TBL] [Abstract][Full Text] [Related]
30. Spanish expert consensus on the use of safinamide in Parkinson's disease.
Valldeoriola F; Grandas F; Arbelo JM; Blázquez Estrada M; Calopa Garriga M; Campos-Arillo VM; Garcia Ruiz PJ; Gómez Esteban JC; Leiva Santana C; Martínez Castrillo JC; Mir P; Salvador Aliaga A; Vivancos Matellano F; Yáñez Baña RM
Neurologia (Engl Ed); 2021; 36(9):666-672. PubMed ID: 34752344
[TBL] [Abstract][Full Text] [Related]
31. Safinamide in the treatment of Parkinson's disease.
Schapira AH
Expert Opin Pharmacother; 2010 Sep; 11(13):2261-8. PubMed ID: 20707760
[TBL] [Abstract][Full Text] [Related]
32. Overall Efficacy and Safety of Safinamide in Parkinson's Disease: A Systematic Review and a Meta-analysis.
Giossi R; Carrara F; Mazzari M; Lo Re F; Senatore M; Schicchi A; Corrù F; Fittipaldo VA; Pani A; Tramacere I; Elia AE; Scaglione F
Clin Drug Investig; 2021 Apr; 41(4):321-339. PubMed ID: 33674954
[TBL] [Abstract][Full Text] [Related]
33. Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.
Schapira AH; Fox SH; Hauser RA; Jankovic J; Jost WH; Kenney C; Kulisevsky J; Pahwa R; Poewe W; Anand R
JAMA Neurol; 2017 Feb; 74(2):216-224. PubMed ID: 27942720
[TBL] [Abstract][Full Text] [Related]
34. Safinamide in the treatment of Parkinson's disease.
Müller T
Neurodegener Dis Manag; 2020 Aug; 10(4):195-204. PubMed ID: 32648512
[TBL] [Abstract][Full Text] [Related]
35. The role of glutamatergic neurotransmission in the motor and non-motor symptoms in Parkinson's disease: Clinical cases and a review of the literature.
Pagonabarraga J; Tinazzi M; Caccia C; Jost WH
J Clin Neurosci; 2021 Aug; 90():178-183. PubMed ID: 34275546
[TBL] [Abstract][Full Text] [Related]
36. Switch from rasagiline to safinamide in fluctuating Parkinson's disease patients: a retrospective, pilot study.
Bianchini E; Sforza M; Rinaldi D; Alborghetti M; De Carolis L; Della Gatta F; Pontieri FE
Neurol Res; 2021 Nov; 43(11):950-954. PubMed ID: 34142645
[TBL] [Abstract][Full Text] [Related]
37. Rasagiline and safinamide as a dopamine-sparing therapy for Parkinson's disease.
Avila A; Caballol N; Martín-Baranera M; Gómez-Ruiz I; Balagué-Marmaña M; Planas-Ballvé A; Cardona X
Acta Neurol Scand; 2019 Jul; 140(1):23-31. PubMed ID: 30963543
[TBL] [Abstract][Full Text] [Related]
38. Real life evaluation of safinamide effectiveness in Parkinson's disease.
Mancini F; Di Fonzo A; Lazzeri G; Borellini L; Silani V; Lacerenza M; Comi C
Neurol Sci; 2018 Apr; 39(4):733-739. PubMed ID: 29441484
[TBL] [Abstract][Full Text] [Related]
39. Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition.
Stocchi F; Vacca L; Grassini P; De Pandis MF; Battaglia G; Cattaneo C; Fariello RG
Neurology; 2006 Oct; 67(7 Suppl 2):S24-9. PubMed ID: 17030737
[TBL] [Abstract][Full Text] [Related]
40. A systematic review and meta-analysis of safety and efficacy of safinamide for motor fluctuations in patients with Parkinson's disease.
Abdelalem Aziz Ahmed M
F1000Res; 2019; 8():2078. PubMed ID: 32431802
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
